[ad_1]
London Agencies
A global alliance has announced an investment of up to $ 8.4 million to develop technology to produce adaptive industrial vaccines tailored to each disease, enabling the fight against many bacteria and viruses.
The alliance, formed at Imperial College, aims to develop a "vaccine platform" using technology that enables ribosome DNA, which represents the genome of a virus strain, to clone and grow. multiply, in order to strengthen its capabilities, known as SA / R. "He said.
The vaccine platform uses basic ingredients and can be modified to immunize against various diseases by adding a new gene sequence of the target disease to prevent it. Robin Chattock, who heads the Imperial team, said the deal could be a huge step forward. Can change the way we look at how vaccines are made. "
Source link
